RankAlpha logo
Back to Rankings

NVS

NovartisB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart

AI scenario view

RankAlpha Sentiment AI
B+
Bull case
25%
Probability
Target price
$175.00
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI
Most likely
B
Base case
55%
Probability
Target price
$144.40
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$109.51
Analysis reference price unavailable
Analysis 2026-02-04 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-02-04
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.4
Score

AI commentary

Market tone is neutral-to-cautiously constructive and supports a 'hold' stance: the base target ($144.4) sits modestly below the anchor price ($149.9), which limits near-term upside absent positive pipeline or margin surprises. Analyst dispersion is wide (highs near $175, lows near $109.51), indicating outcome-driven volatility—positive readouts or better-than-expected guidance could push toward the bull case, while regulatory setbacks or accelerated biosimilar pressure could drive the stock toward the bear case. Expect short-term choppy trading as analysts update models after results [#PR-2026-02-04][#SERP-2].

RankAlpha Sentiment AI - 2026-02-04
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-02-04eventFY2025 Earnings ReleaseMedium impact

Full-year 2025 results and updated guidance; market reaction possible on revenue/margin beats or guidance changes [#SERP-5].

2027-02-04catalystLate-stage approvals / launches and biosimilars expansionHigh impact

Regulatory approvals or major product launches (including biosimilars/oncology assets) could materially shift revenue profile; date is an assumed 12-month horizon for conservatism.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-02-04 • Updated nightlySource: Internal modelMethodology